People
As an immigrant, female, mid-30’s CEO in the biotech world, Leen Kawas is used to being told no. She’s familiar with doubts being cast on her ideas, eyebrows raised at her push for innovation and some flat out telling her it won’t work. And she’s comfortable with all of that. It’s that grit that’s gotten her to where she is now.
While Sutro’s technological platform opens multiple therapeutic doors, the company’s singular focus on homogeneous molecules is a key part of its competitive strategy.
Biotech CFOs, optimistic about economic recovery as COVID-19 vaccines role out, are busy digitally transforming their companies for a post-COVID way of working, according to the 2021 BDO Life Sciences CFO Outlook Survey, released January 11.
The lessons learned from the global pandemic are expected to translate to existing and emerging therapeutic areas - particularly oncology; more efficient regulatory-industry relationships; mRNA is a word we will continue to hear a lot about; and home health care is here to stay.
BioSpace spoke to executives from four companies about their expectations for the conference and the coming year.
Frank Nestle, Sanofi’s chief scientific officer and Global Head of Research, and Dietmar Berger, Sanofi’s chief medical officer and Global Head of Development, provided an overview of the company’s clinical activities and highlighted some assets that will be key revenue drives for the company.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
With the new year comes a changing of the guard at Pfizer. After two years of helming the company’s pharma operations, Chief Medical Officer Mace Rothenberg announced his departure from Pfizer on social media.
Dr. Lynn Seely bows out as Myovant pivots to commercialize new drug.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
PRESS RELEASES